Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2441-2447
© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype
From the Departments of Medicine, Division of Medical Genetics (G.P.J., L.S.R., V.H.B., R.J.R., C.E.F.), Epidemiology (G.P.J., L.S.R.), Neurology (G.D.S.), and Genetics (C.E.F.), University of Washington, and the Puget Sound Veterans Affairs Health Care System (T.S.H., G.D.S.), Seattle, Wash.
Correspondence to Gail Jarvik, MD, PhD, University of Washington Medical Center, Division of Medical Genetics, Box 357720, Seattle, WA 98195-7720. Pair@u.washington.edu
Abstract—The paraoxonase (PON1) PON1-Q192R and PON1-L55M polymorphisms have been inconsistently associated with vascular disease. Plasma PON1 activity phenotypes vary markedly within genotypes and were, therefore, expected to add to the informativeness of genotype for predicting vascular disease. The case-control sample included 212 age- and race-matched men (mean age 66.4 years). The 106 carotid artery disease (CAAD) cases had >80% carotid stenosis, and the 106 controls had <15%. Two PON1 substrate hydrolysis rates (paraoxon [POase] and diazoxon [DZOase]) were significantly lower in cases than in controls and were significant predictors of CAAD by use of logistic regression (POase, P=0.005; DZOase, P=0.019). DZOase predicted vascular disease independently of lipoprotein profile, high density lipoprotein subfractions, apolipoprotein A-I, and smoking. PON1-192 and PON1-55 genotypes or haplotypes did not predict case-control status unless the activity phenotype was also included as a predictor by use of logistic regression. When phenotype was included as a predictor, PON1-192 and PON1-55 genotypes or combined haplotypes were significant predictors (P<0.05). In conclusion, examining PON1-192 and/or PON1-55 genotypes alone may mistakenly lead to the conclusion that there is no role of PON1 in CAAD. These results support the benefit of a "level crossing" approach that includes intervening phenotypes in the study of complexly inherited disease.
Key Words: paraoxonase • genotypes • phenotypes • carotid artery disease • vascular disease
This article has been cited by other articles:
 |
|
 |
|
  B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study Clin. Chem., April 1, 2008; 54(4): 738 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. -M. Wills, J. E. Landers, H. Zhang, R. J. Richter, A. J. Caraganis, M. E. Cudkowicz, C. E. Furlong, and R. H. Brown Jr Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS Neurology, March 18, 2008; 70(12): 929 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Crawford, A. S. Nord, M. D. Badzioch, J. Ranchalis, L. A. McKinstry, M. Ahearn, C. Bertucci, C. Shephard, M. Wong, M. J. Rieder, et al. A common VLDLR polymorphism interacts with APOE genotype in the prediction of carotid artery disease risk J. Lipid Res., March 1, 2008; 49(3): 588 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Verit, O. Erel, and N. Celik Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease Hum. Reprod., January 1, 2008; 23(1): 100 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sarandol, S. Kirli, C. Akkaya, N. Ocak, E. Eroz, and E. Sarandol Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment J Psychopharmacol, November 1, 2007; 21(8): 857 - 863. [Abstract] [PDF]
|
|
|
|
|
|
L. Gaidukov and D. S. Tawfik The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity J. Lipid Res., July 1, 2007; 48(7): 1637 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kriska, G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti Phospholipase Action of Platelet-activating Factor Acetylhydrolase, but Not Paraoxonase-1, on Long Fatty Acyl Chain Phospholipid Hydroperoxides J. Biol. Chem., January 5, 2007; 282(1): 100 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Ng, N. Bourquard, V. Grijalva, S. Hama, D. M. Shih, M. Navab, A. M. Fogelman, A. J. Lusis, S. Young, and S. T. Reddy Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins: ANTI-ATHEROGENIC ROLE FOR PARAOXONASE-2 J. Biol. Chem., October 6, 2006; 281(40): 29491 - 29500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Slowik, B. Tomik, P. P. Wolkow, D. Partyka, W. Turaj, M. T. Malecki, J. Pera, T. Dziedzic, A. Szczudlik, and D. A. Figlewicz Paraoxonase gene polymorphisms and sporadic ALS Neurology, September 12, 2006; 67(5): 766 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saeed, N. Siddique, W. Y. Hung, E. Usacheva, E. Liu, R. L. Sufit, S. L. Heller, J. L. Haines, M. Pericak-Vance, and T. Siddique Paraoxonase cluster polymorphisms are associated with sporadic ALS Neurology, September 12, 2006; 67(5): 771 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Marchegiani, M. Marra, L. Spazzafumo, R. W. James, M. Boemi, F. Olivieri, M. Cardelli, L. Cavallone, A. R. Bonfigli, and C. Franceschi Paraoxonase activity and genotype predispose to successful aging. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Carlson, P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease J. Lipid Res., May 1, 2006; 47(5): 1014 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Liu, P.-L. Huang, Y.-F. Chang, Y.-H. Chen, Y.-H. Chiou, Z.-L. Xu, and R.-H. Wong GSTP1 Genetic Polymorphism Is Associated with a Higher Risk of DNA Damage in Pesticide-Exposed Fruit Growers. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Blatter Garin, X. Moren, and R. W. James Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I J. Lipid Res., March 1, 2006; 47(3): 515 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Shih, H. R. Kast-Woelbern, J. Wong, Y.-R. Xia, P. A. Edwards, and A. J. Lusis A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids J. Lipid Res., February 1, 2006; 47(2): 384 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Erlich, K. L. Lunetta, L. A. Cupples, M. Huyck, R. C. Green, C. T. Baldwin, L. A. Farrer, and for the MIRAGE Study Group Polymorphisms in the PON gene cluster are associated with Alzheimer disease Hum. Mol. Genet., January 1, 2006; 15(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dursun, E. Demirtas, A. Bayrak, and H. Yarali Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum. Reprod., January 1, 2006; 21(1): 104 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome Endocr. Rev., April 1, 2005; 26(2): 251 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Manolio, E. Boerwinkle, C. J. O'Donnell, and A. F. Wilson Genetics of Ultrasonographic Carotid Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1567 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. San Millan, M. Corton, G. Villuendas, J. Sancho, B. Peral, and H. F. Escobar-Morreale Association of the Polycystic Ovary Syndrome with Genomic Variants Related to Insulin Resistance, Type 2 Diabetes Mellitus, and Obesity J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2640 - 2646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Jarvik, T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study Circulation, June 10, 2003; 107(22): 2775 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kopprasch, J. Pietzsch, E. Kuhlisch, and J. Graessler Lack of Association between Serum Paraoxonase 1 Activities and Increased Oxidized Low-Density Lipoprotein Levels in Impaired Glucose Tolerance and Newly Diagnosed Diabetes Mellitus J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1711 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Cabana, C. A. Reardon, N. Feng, S. Neath, J. Lukens, and G. S. Getz Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response J. Lipid Res., April 1, 2003; 44(4): 780 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre Platelet-activating Factor Acetylhydrolase, and Not Paraoxonase-1, Is the Oxidized Phospholipid Hydrolase of High Density Lipoprotein Particles J. Biol. Chem., January 31, 2003; 278(6): 3937 - 3947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rantala, M.-L. Silaste, A. Tuominen, J. Kaikkonen, J. T. Salonen, G. Alfthan, A. Aro, and Y. A. Kesaniemi Dietary Modifications and Gene Polymorphisms Alter Serum Paraoxonase Activity in Healthy Women J. Nutr., October 1, 2002; 132(10): 3012 - 3017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jakubowski Homocysteine Is a Protein Amino Acid in Humans. IMPLICATIONS FOR HOMOCYSTEINE-LINKED DISEASE J. Biol. Chem., August 16, 2002; 277(34): 30425 - 30428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Jarvik, N. T. Tsai, L. A. McKinstry, R. Wani, V. H. Brophy, R. J. Richter, G. D. Schellenberg, P. J. Heagerty, T. S. Hatsukami, and C. E. Furlong Vitamin C and E Intake Is Associated With Increased Paraoxonase Activity Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1329 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tward, Y.-R. Xia, X.-P. Wang, Y.-S. Shi, C. Park, L. W. Castellani, A. J. Lusis, and D. M. Shih Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice Circulation, July 23, 2002; 106(4): 484 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barbieri, M. Bonafe, R. Marfella, E. Ragno, D. Giugliano, C. Franceschi, and G. Paolisso LL-Paraoxonase Genotype Is Associated with a More Severe Degree of Homeostasis Model Assessment IR in Healthy Subjects J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 222 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Mackness, G. K. Davies, W. Turkie, E. Lee, D. H. Roberts, E. Hill, C. Roberts, P. N. Durrington, and M. I. Mackness Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1451 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Hokanson Gene-Environment Interaction in the Expression of Antioxidant Status : A Role for Genes in the Relationship Between Smoking and Coronary Disease Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1102 - 1103. [Full Text] [PDF]
|
|